Investors
Investors
Creating value for stakeholders
We are an established, commercial-stage diagnostics company.
We are an established, commercial-stage diagnostics company with over 30 years’ experience of manufacturing and supplying the conventional reagent products used for blood grouping within the $3.4 billion global transfusion diagnostics market.


Our proprietary technology platform, MosaiQ, is continually been developed and enhanced to better address the comprehensive needs of this large and established market. We believe MosaiQ has the potential to be a transformative technology that significantly reduces the cost of blood grouping in both donor and patient-testing environments.

Investors

3:53 PM EDT • Aug 8, 2022
QTNT
0.2857USD
14.79%
Contact

Ali Kiboro, Chief Financial Officer 

IR@quotientbd.com

3 Months
6 Months
12 Months
Quotient Ltd
$
Events & Presentations
Quotient Limited Provides Fourth Quarter Fiscal 2022 Results and Business Update
June 24, 2022

Events & presentations

Quotient Limited to Report First Quarter Fiscal 2023 Financial Results and Host Conference Call
Quotient Limited to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call

Press releases

Quotient Limited to Report First Quarter Fiscal 2023 Financial Results and Host Conference Call on August 9th
Quotient Limited and InfYnity Biomarkers Announce Partnership to Expand MosaiQ Infectious Disease Menu
Quotient Limited Announces Equity Awards
Financials & filings

Get up-to-date information about our Company’s financials.

Corporate governance

Retrieve corporate policy documents, committee charters, and more. 

Stock information

Follow our latest stock quote and historical information.